Patent application EP17306037A (EP), filed 2017-08-03
Publication number: EP3437651A1
Title: PEPTIDES FOR TREATMENT AND PREVENTION OF NONALCOHOLIC FATTY LIVER DISEASE
Abstract: The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver fibrosis, liver inflammation, cirrhosis, or hepatocellular carcinoma.
IPC codes: A61K  38/    08            A I
A61K  38/    10            A I
A61K  38/    16            A I
A61K  38/    45            A I
A61P   1/    16            A I
C12N   9/    12            A I
Claims: number: 1
text: A peptide for use in the treatment or prevention of a disease selected from the group consisting of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver fibrosis, liver inflammation, cirrhosis, or hepatocellular carcinoma, wherein
number: 2
text: The peptide for use according to claim 1, wherein the peptide preferably adopts an alpha helical conformation.
number: 3
text: The peptide for use according to claim 1 or 2, wherein the peptide is modified by a chemical cross-linking process such as stapling.
number: 4
text: The peptide for use according to anyone of claims 1-3, wherein the peptide sequence comprises a sequence according to one of the following formulae:
number: 5
text: The peptide for use according to anyone of claims 1-4, wherein the peptide comprises a sequence according to one of the following formulae:
number: 6
text: The peptide for use according to any one of claims 1-5, wherein m + n is less than 20 and m and n are an integer from 2 to 15, preferably from 2 to 7.
number: 7
text: The peptide for use according to any one of claims 1-6, wherein said PKC is selected from the group consisting of an alpha-PKC (αPKC), a beta-PKC (βPKC) including βI and βII PKC, delta-PKC, theta-PKC, eta-PKC and epsilon-PKC.
number: 8
text: The peptide for use according to claim 7, wherein said PKC is an αPKC of SEQ ID No 1.
number: 9
text: The peptide for use according to any one of claims 1-8, wherein the peptide sequence comprises a sequence selected from the group consisting of:
number: 10
text: The peptide for use according to claim 9, wherein the peptide sequence comprises a sequence selected from the group consisting of:
number: 11
text: The peptide for use according to any one of claims 1-10, wherein the peptide sequence comprises or consists in a sequence selected from the group consisting of:
number: 12
text: The peptide for use according to anyone of claims 1-11, wherein the peptide consists in a sequence selected from the group consisting of:
number: 13
text: The peptide for use according to anyone of claims 1-11, wherein the disease is selected from the group consisting of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), and hepatic steatosis (fatty liver).
number: 14
text: The peptide for use according to anyone of claims 1-11, wherein the disease is hepatic steatosis (fatty liver) or non-alcoholic steatohepatitis (NASH).
number: 15
text: The peptide for use according to anyone of claims 1-11, wherein the disease is non-alcoholic steatohepatitis (NASH).
Office action: search_report, dated 2019-02-06
Prior art cited: ref_id: WO2010033617A2
ref_type: patent
severity: background
ref_id: WO2010011313A2
ref_type: patent
severity: background
ref_id: WO2005117830A1
ref_type: patent
severity: background
ref_id: WO2006075124A1
ref_type: patent
severity: background
ref_id: WO2004103995A1
ref_type: patent
severity: background
ref_id: WO03043985A1
ref_type: patent
severity: background
ref_id: WO2010033617A2
ref_type: patent
severity: background
ref_id: - DATABASE UniProt [O] Database accession no. Q8TCU4
ref_type: npl
severity: background
ref_id: - DATABASE Gene [O] Database accession no. 7840
ref_type: npl
severity: background
ref_id: - DATABASE Genbank [O] Database accession no. NM_015120.4
ref_type: npl
severity: background
ref_id: - DATABASE GENBANK [O] Database accession no. NP_055935.4
ref_type: npl
severity: background
ref_id: - DATABASE UniProt [O] Database accession no. P17252
ref_type: npl
severity: background
ref_id: - DATABASE Gene [O] Database accession no. 9393
ref_type: npl
severity: background
ref_id: - DATABASE Genbank [O] Database accession no. NM_02737.2
ref_type: npl
severity: background
ref_id: - DATABASE Genbank [O] Database accession no. NP_002728.1
ref_type: npl
severity: background
ref_id: - BEDGNI ET AL., BMC GASTROENTEROL, vol. 6, 2 November 2006 (2006-11-02), pages 33
ref_type: npl
severity: background
ref_id: - TOLMAN; DALPIAZ, THER. CLIN. RISK. MANAG., vol. 3, no. 6, 2007, pages 1153 - 1163
ref_type: npl
severity: background
ref_id: - FRISHMAN D.; ARGOS P., PROTEINS, vol. 23, no. 4, 1995, pages 566 - 579
ref_type: npl
severity: background
ref_id: - RICHARDS F. M.; KUNDROT C. E., PROTEINS, vol. 3, no. 2, 1988, pages 71 - 84
ref_type: npl
severity: background
ref_id: - TOUW ET AL., NUCLEIC ACIDS RESEARCH, vol. 43, 2015, pages D364 - D368
ref_type: npl
severity: background
ref_id: - KABSCH; SANDER, BIOPOLYMERS, vol. 22, 1983, pages 2577 - 2637
ref_type: npl
severity: background
ref_id: - VERDINE; HILINSKI, METHODS ENZYMOL, vol. 503, 2012, pages 3 - 33
ref_type: npl
severity: background
ref_id: - DATABASE UniProtKB [O] Database accession no. 014975
ref_type: npl
severity: background
ref_id: - DATABASE UniGene [O] Database accession no. Hs.11729
ref_type: npl
severity: background
ref_id: - MATSUSHITA; MATSUI, J MOL MED, vol. 83, 2005, pages 324 - 328
ref_type: npl
severity: background
ref_id: - VIVES ET AL., BIOCHIMIC ET BIOPHYSICA ACTA, vol. 1786, 2008, pages 126 - 138
ref_type: npl
severity: background
ref_id: - EXPERT OPIN INVESTIG DRUGS, vol. 12, no. 4, 2003, pages 623 - 633
ref_type: npl
severity: background
ref_id: - J. SWARBRICK AND J. C. BOYLAN: "Encyclopedia of Pharmaceutical Technology", 1988, MARCEL DEKKER
ref_type: npl
severity: background
ref_id: US2013303554A1
ref_type: patent
severity: background
ref_id: WO2013133667A1
ref_type: patent
severity: background
ref_id: - VARMAN T. SAMUEL ET AL: "Inhibition of protein kinase C[epsilon] prevents hepatic insulin resistance in nonalcoholic fatty liver disease", JOURNAL OF CLINICAL INVESTIGATION, vol. 117, no. 3, 1 March 2007 (2007-03-01), pages 739 - 745, XP055032877, ISSN: 0021-9738, DOI: 10.1172/JCI30400
ref_type: npl
severity: background
ref_id: - KATOH N ET AL: "Decreased protein kinase C activity in fatty liver from cattle.", AMERICAN JOURNAL OF VETERINARY RESEARCH, vol. 50, no. 9, September 1989 (1989-09-01), pages 1489 - 1492, XP009501927, ISSN: 0002-9645
ref_type: npl
severity: background
ref_id: - MOYA MARTA ET AL: "Foxa1 reduces lipid accumulation in human hepatocytes and is down-regulated in nonalcoholic fatty liver.", PLOS ONE, vol. 7, no. 1, E30014, 2012, pages 1 - 17, XP002776408, ISSN: 1932-6203
ref_type: npl
severity: background
ref_id: WO2013133667
ref_type: patent
severity: background
ref_id: US2013303554
ref_type: patent
severity: background
ref_id: - VARMAN T. SAMUEL ET AL, "Inhibition of protein kinase C[epsilon] prevents hepatic insulin resistance in nonalcoholic fatty liver disease", JOURNAL OF CLINICAL INVESTIGATION, (20070301), vol. 117, no. 3, doi:10.1172/JCI30400, ISSN 0021-9738, pages 739 - 745, XP055032877 [A] 1-15 * abstract *
ref_type: npl
severity: background
ref_id: - KATOH N ET AL, "Decreased protein kinase C activity in fatty liver from cattle.", AMERICAN JOURNAL OF VETERINARY RESEARCH, (198909), vol. 50, no. 9, ISSN 0002-9645, pages 1489 - 1492, XP009501927 [A] 1-15 * abstract *
ref_type: npl
severity: background
ref_id: - MOYA MARTA ET AL, "Foxa1 reduces lipid accumulation in human hepatocytes and is down-regulated in nonalcoholic fatty liver.", PLOS ONE, (2012), vol. 7, no. 1, ISSN 1932-6203, pages 1 - 17, XP002776408 [A] 1-15 * abstract *
ref_type: npl
severity: background
Final disposition: pending (2019-02-06)